Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its second-quarter 2026 financial results, revealing a substantial reduction in operating expenses and a key regulatory milestone for its lead drug candidate. The company reported a 53% year-over-year decrease in operating expenses to $2.29 million, and general and administrative expenses fell by 47% to $1.76 million. As of June 30, the company held approximately $9.5 million in cash, cash equivalents, and digital assets, a significant increase from $4.1 million at the end of 2025. Management states that current liquidity will fund planned operations to at least October 2027, assuming the first-half 2026 cash burn rate.
More importantly, subsequent to quarter-end, the U.S. Food and Drug Administration (FDA) approved Quantum’s Investigational New Drug (IND) application for Lucid-MS. This approval allows the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis (MS). Lucid-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. This advancement is a critical step toward a potential treatment for a condition that currently has limited therapeutic options, especially for the progressive form of the disease.
The cost reductions and the FDA approval signal a strategic focus on efficient development of its pipeline. Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Its wholly-owned subsidiary, Lucid Psycheceuticals Inc., is leading the research and development of Lucid-MS. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets an over-the-counter version of its UNBUZZD product, and is entitled to royalty payments from Unbuzzd sales, providing additional potential revenue streams.
The approval of the IND application is a significant milestone for Quantum BioPharma and for patients with progressive MS, as it advances a potential therapy that targets the root cause of the disease. The initiation of the Phase 2 trial will provide critical data on the efficacy and safety of Lucid-MS in humans. If successful, Lucid-MS could become a first-in-class treatment, addressing a high unmet medical need.
For more details, the full press release is available at https://nnw.fm/dlAAe. Information about the company’s recent news can be found at https://ibn.fm/QNTM.
